Recovery · Reference
ARA-290 Benefits: What the Research Actually Shows
This page goes benefit by benefit, names the study and the population behind each finding and its limits, and then covers side effects, FDA status and how Pepti supplies it. For the full product reference, see what is ARA-290.
Treatments mentioned
ARA-290, also called cibinetide, is one of the few compounded peptides with randomized, placebo-controlled human trials, but they were small, four weeks long, run by the developer, and limited to two groups: people with sarcoidosis-related small-fibre neuropathy and people with type 2 diabetes and painful neuropathy. The most consistent finding is an increase in small nerve fibres counted by a corneal eye scan, alongside better scores on neuropathy symptom questionnaires. Pain intensity did not clearly separate from placebo, no phase 3 trial exists, and the "recovery" and injury uses rest on animal work. Every benefit below is something research has looked at, not something an injection can promise.
This page goes benefit by benefit, names the study and the population behind each finding and its limits, and then covers side effects, FDA status and how Pepti supplies it. For the full product reference, see what is ARA-290.
ARA-290 Benefits
The short answer
| Claimed benefit | What the evidence is | Strength of evidence |
|---|---|---|
| Small nerve fibre regrowth | Human (randomized phase 2 trials, corneal nerve counts; one skin biopsy finding) | The most consistent signal, in two specific populations, measured at four weeks |
| Neuropathy symptoms | Human (randomized trials, symptom questionnaires) | Separated from placebo on questionnaires in small trials |
| Pain intensity | Human (randomized trials) | Not clearly better than placebo |
| Physical function | Human (one 2013 trial, six-minute walk) | Single small trial |
| Blood sugar and lipids | Human (one 2015 phase 2 trial); animal | Preliminary; not replicated |
| Inflammation in nerve tissue | Animal (rats and mice) | Preclinical only |
| Recovery, injury and performance | Animal work and mechanism | No human data |
| Diabetic eye disease | Human (one 2020 open-label study, 9 people) | No improvement found |
| Mood | Human (one single-dose study in 36 healthy volunteers) | No effect found |
Pepti supplies ARA-290 as a 5 mL vial at 2 mg/mL (10 mg per vial) for $219/mo, all-in.
ARA-290 Benefits
What ARA-290 is, briefly
ARA-290 is an eleven-amino-acid peptide whose sequence was lifted from one helix of erythropoietin, the hormone that tells bone marrow to make red blood cells. The 2008 paper in the Proceedings of the National Academy of Sciences that introduced it described "nonerythropoietic, tissue-protective peptides": keep the part of erythropoietin that appears to protect tissue, leave behind the part that raises red cell counts. Erythropoietin itself had been studied for nerve, heart and kidney protection and kept running into the same problem: at the doses needed, it thickens the blood and raises clotting risk.
ARA-290 is described as engaging only a second receptor assembly, one erythropoietin receptor paired with the beta-common receptor (CD131), which the research group named the "innate repair receptor" and describes as switched on in injured or inflamed tissue. A 2011 study in Anesthesiology found that in mice bred without the beta-common receptor, ARA-290 did nothing, which is the clearest evidence for that mechanism. It does not raise haemoglobin. It is not an analgesic in the usual sense; it does not act on sodium channels or opioid receptors.
ARA-290 Benefits
Benefit by benefit
1. Small nerve fibre regrowth
What the research describes. Small nerve fibres carry pain and temperature and run the autonomic system; they are what is lost in small-fibre neuropathy. The trials counted them with corneal confocal microscopy, a non-invasive eye scan used as a stand-in for fibre density elsewhere. In the 2013 subcutaneous sarcoidosis trial in Molecular Medicine, corneal nerve fibre density increased. In the 2015 diabetes trial, it increased in the subset who started with clearly reduced density and did not change on placebo. The largest trial, a 2017 phase 2b dose-ranging study of 64 people in Investigative Ophthalmology and Visual Science, used change in corneal nerve fibre area as its primary endpoint; the middle dose beat placebo and also increased regenerating fibres in skin biopsy.
What it does not show. Only one of the three doses in the 2017 trial reached significance; the low and high doses did not. A 2016 review in Pain Reports notes that in an earlier trial, regrowth was seen in the cornea but not in the skin. Corneal counts are a surrogate, not a hard outcome, and nothing was measured beyond four weeks of treatment.
2. Neuropathy symptoms
What the research describes. In the first trial, a 2012 pilot in Molecular Medicine, 22 people with sarcoidosis and small-fibre neuropathy symptoms received ARA-290 by vein three times a week for four weeks, or placebo. The treated group improved more than placebo on the Small Fiber Neuropathy Screening List, a symptom questionnaire. In the 2015 diabetes trial, symptoms on the PainDetect questionnaire improved significantly with 28 days of daily subcutaneous ARA-290.
What it does not show. In the 2012 pilot, the Brief Pain Inventory pain score and the fatigue score improved equally in both groups, and depressive symptoms did not change. The trials were small and run by the developer. They do not establish benefit in neuropathy from other causes, such as chemotherapy, alcohol or injury, because those groups were not studied.
3. Pain intensity
What the research describes. Pain is the reason most people ask about ARA-290, so this is where precision matters. In the 2017 phase 2b trial, pain improved in every group, including placebo. At the middle dose, the placebo-corrected reduction in pain intensity was described as clinically meaningful in those with moderate-to-severe pain.
What it does not show. That reduction was not statistically significant. Across the trials, the symptom questionnaires separated from placebo and the pain-intensity scores did not. ARA-290 is not a fast-acting painkiller, and the evidence for pain relief beyond placebo is weaker than marketing usually implies.
4. Physical function
What the research describes. The 2013 subcutaneous sarcoidosis trial added objective measures, and six-minute walk distance increased in treated patients. The 2012 pilot reported improvement from baseline on the physical-functioning part of the SF-36 questionnaire.
What it does not show. One small trial for the walk test, in one disease. It is not evidence about fitness or performance in healthy people.
5. Blood sugar and lipids
What the research describes. This was not the original target. In the 2015 phase 2 study in Molecular Medicine, people with type 2 diabetes and painful neuropathy who took ARA-290 for 28 days showed improved haemoglobin A1c and lipid profiles compared with placebo, and these persisted through a month of follow-up. A 2016 study in diabetic rats reported improved insulin release and glucose tolerance.
What it does not show. One trial, not replicated, with the human mechanism not established. It has not been taken into a larger trial. It is a reason for anyone on glucose-lowering medication to list it at intake, not a reason to take ARA-290 for blood sugar.
6. Inflammation in nerve tissue
What the research describes. A 2014 paper in Molecular Pain reported that five doses in the first ten days after a nerve injury in rats reduced pain-related behaviour for up to twenty weeks and suppressed activation of spinal cord microglia, the immune cells thought to sustain neuropathic pain. The 2016 review frames this as reprogramming a tissue-damaging environment into one of repair.
What it does not show. That is the authors' hypothesis with animal support, not a demonstrated human mechanism.
7. Recovery, injury and performance
What the research describes. ARA-290 sits in Pepti's Recovery category, and it is sometimes discussed for general recovery. The support for that is the animal nerve-injury work and the receptor mechanism.
What it does not show. There is no human data for musculoskeletal injury, general recovery or performance. A tendon, ligament or muscle problem is where BPC-157, TB-500 or the BPC-157 + TB-500 stack are usually discussed; see BPC-157 vs TB-500.
8. The eye and mood
What the research describes. A 2020 open-label study in the Journal of Clinical Medicine gave nine people with diabetic macular oedema twelve weeks of daily cibinetide. A 2015 single-dose study in 36 healthy volunteers in European Neuropsychopharmacology looked at mood.
What it does not show. The eye study found no improvement in visual acuity or retinal thickness, though the course was safe and no antibodies to the peptide were detected. The mood study found no effect. Neither is a success, and an honest page says so.
ARA-290 Benefits
What the evidence shows, honestly
| What the trials had | What they lacked |
|---|---|
| Randomized, double-blind, placebo-controlled designs | Size: 22 to 64 people per trial |
| A consistent nerve-fibre signal on corneal scans | Hard outcomes; corneal counts and questionnaires are surrogates |
| Subcutaneous daily dosing, the route Pepti uses | Independent replication; the developer's group ran the work |
| A clean safety record over four weeks | Any data beyond four weeks of treatment |
| Two defined patient populations | Any data in other causes of nerve pain, or in healthy people |
The fair summary: a consistent signal on small nerve fibre regrowth and neuropathy symptom questionnaires in two specific patient populations, a clean safety record over four-week courses, and no proof of durable pain relief or of benefit in any other condition. These findings are research in diagnosed populations. They are not a claim that ARA-290 treats neuropathy or any disease, and compounded ARA-290 is not approved for anything. Neuropathy also has testable causes, such as B12 deficiency, thyroid disease and poorly controlled glucose, which are worth working up first.
ARA-290 Benefits
ARA-290 side effects
Across the human trials, intravenous and subcutaneous, in sarcoidosis, type 2 diabetes, diabetic macular oedema and healthy volunteers, investigators reported no safety concerns from clinical or laboratory assessments. The design purpose, no effect on red cell production, held up, so it does not carry erythropoietin's clotting risk. That is a clean record over short courses in small groups; long-term data does not exist.
| What is reported | What to do |
|---|---|
| Injection-site redness, mild soreness, occasional bruising | Rotate sites between abdomen and thigh |
| Blood sugar changes if you take insulin or other glucose-lowering medication | A precaution from one trial's HbA1c finding; list it at intake and report symptoms |
| A reaction that is severe, spreading or involves difficulty breathing | Emergency care first (call 911), then tell your physician |
There is no established interaction list, which is why the intake asks for every medication you take. ARA-290 is not used in pregnancy or breastfeeding, where safety data is absent. It is named as a prohibited peptide in the anti-doping literature, so tested athletes should check the current list for their sport.
ARA-290 Benefits
Where ARA-290 stands with the FDA
As of the FDA's document updated 14 May 2026, cibinetide (ARA-290) is in Category 3 of substances nominated for the 503A bulks list, "Bulk Drug Substances Nominated Without Adequate Support." That is a paperwork category, not a safety finding: the nomination did not include enough supporting information for the FDA to evaluate it. It is not on the Category 2 list of substances with significant safety risks, current as of 22 April 2026, and it was not among the peptides the Pharmacy Compounding Advisory Committee discussed on 23 and 24 July 2026. It has never been submitted for FDA approval as a drug. Compounded medications are not FDA approved.
ARA-290 Benefits
How Pepti supplies it
| Detail | ARA-290 |
|---|---|
| Product | ARA-290, injectable |
| What is in the vial | 5 mL multi-dose vial, 2 mg/mL (10 mg ARA-290) |
| Standard directions | 0.25 mL (25 units) subcutaneously once daily Monday through Friday |
| Per dose | 0.5 mg |
| Doses per vial | 20, about four weeks |
| Format | Vial and syringe only; no pen, capsule or nasal spray |
| Price | $219/mo, all-in |
The price covers medication, physician review, refill management and shipping, with no membership fee, and Pepti does not bill insurance. Refills run every 28 days, one vial per fill. The vial arrives as a solution ready to use, with directions printed on it, sterile syringes and alcohol prep pads, shipped refrigerated with ice packs. Lot test results are at /quality/lab-results. The units, mL and mg detail is in ARA-290 dosage.
ARA-290 Benefits
Where to get ARA-290 prescribed
ARA-290 cannot be bought legitimately without a prescription. Sites selling it "for research use only" are not accountable for identity, purity, sterility or concentration. The prescription route:
- Complete a free online intake covering your history, medications and what you want help with.
- A physician licensed in your state reviews it, usually within 24 hours.
- If it is appropriate, a PCAB-accredited, FDA-registered US 503A pharmacy compounds it to that prescription. Lot test results are published at /quality/lab-results.
- It ships refrigerated with your directions printed on the vial.
- Your physician stays reachable for questions and dose changes.
Pepti prescribes ARA-290 in every state except Oklahoma, plus DC
References
What this is based on.
References
- Dahan A, Dunne A, Swartjes M et al.. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density · Mol Med (2013) · PMID 24136731
- Heij L, Niesters M, Swartjes M et al.. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study · Mol Med (2012) · PMID 23168581
- Brines M, Patel NS, Villa P et al.. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin · Proc Natl Acad Sci U S A (2008) · PMID 18676614
- Swartjes M, Morariu A, Niesters M et al.. ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and β-common receptor knockout mice · Anesthesiology (2011) · PMID 21873879
- Swartjes M, van Velzen M, Niesters M et al.. ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response · Mol Pain (2014) · PMID 24529189
- van Velzen M, Heij L, Niesters M et al.. ARA 290 for treatment of small fiber neuropathy in sarcoidosis · Expert Opin Investig Drugs (2014) · PMID 24555851
- Brines M, Dunne AN, van Velzen M et al.. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes · Mol Med (2015) · PMID 25387363
- Cerit H, Veer IM, Dahan A et al.. Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action · Eur Neuropsychopharmacol (2015) · PMID 26431906
- Dahan A, Brines M, Niesters M et al.. Targeting the innate repair receptor to treat neuropathy · Pain Rep (2016) · PMID 29392190
- Culver DA, Dahan A, Bajorunas D et al.. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain · Invest Ophthalmol Vis Sci (2017) · PMID 28475703
- Thomas A, Knoop A, Schänzer W et al.. Characterization of in vitro generated metabolites of selected peptides <2 kDa prohibited in sports · Drug Test Anal (2017) · PMID 28941172
- Brines M, Culver DA, Ferdousi M et al.. Corneal nerve fiber size adds utility to the diagnosis and assessment of therapeutic response in patients with small fiber neuropathy · Sci Rep (2018) · PMID 29549285
Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.
Common questions
ARA-290 Benefits, answered.
Research describes an increase in small nerve fibres on corneal scans and better neuropathy symptom questionnaire scores after four weeks, in small randomized trials in sarcoidosis and type 2 diabetes. Pain intensity did not clearly beat placebo, and there is no human data for other uses.
Its human trials were in small-fibre neuropathy linked to sarcoidosis and in painful diabetic neuropathy. It is not approved for any condition, and compounded ARA-290 is not FDA approved.
The trials found improvements on symptom questionnaires, but pain-intensity scores improved in placebo groups almost as much and did not separate significantly. It is not a fast-acting painkiller.
The most consistent trial finding is an increase in corneal nerve fibre density or area, used as a stand-in for small fibres elsewhere, with one trial also reporting more regenerating fibres in skin biopsy. It was measured at four weeks in two populations.
There is no human data for musculoskeletal injury or general recovery. Those uses rest on animal nerve-injury work and the receptor mechanism.
One 2015 phase 2 trial in type 2 diabetes reported improved HbA1c and lipids compared with placebo. It has not been replicated, and anyone on glucose-lowering medication should list it at intake.
The trials measured outcomes at 28 days, and that is the only window with human data. No trial has shown what happens earlier or with longer courses, so no timeline can be promised.
No. It was engineered not to bind the receptor pair that drives red cell production, and the trials confirmed no effect on blood counts.
The trials reported no safety concerns over four- to twelve-week courses and no antibodies against the peptide. In practice, what is reported is mostly injection-site redness, soreness or bruising. Long-term safety data does not exist.
No. Cibinetide is in Category 3 of the FDA's 503A nominations list, meaning the nomination lacked enough support to be evaluated, and it is not on the safety-concerns list. Compounded medications are not FDA approved.
Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account. The free assessment goes to a physician licensed in your state. A consultation does not guarantee a prescription.
Next step
See what a physician recommends for you.
A licensed physician in your state reviews your intake and decides what is appropriate. A consultation does not guarantee a prescription.